Tag: Allergan

Allergan is a multi-national pharmaceutical that produces branded and generic drugs, and performs pharmaceutical research and development. Formerly known as Actavis.

Allergan and Exicure Entered into Global Collaboration Agreement

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals ...

FDA Granted Qualified Infectious Disease Product and Fast Track Designation for ATM-AVI

allergan
Allergan plc announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for ATM-AVI (aztreonam and avibactam),...

Allergan Agreed to Pay $750m to Settle Alzheimer’s Lawsuits

Allergan has agreed to pay $750 million to settle lawsuits in the US brought by direct purchasers of its Namenda Alzheimer’s drug in the US. The settlement means that Dublin, Ireland headquartered ...

FDA Approved Allergan sBLA for BOTOX

Allergan plc announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 t...

Allergan Shareholders Approved Proposed Acquisition of Allergan by AbbVie

Allergan plc announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc. As described below, more than 99 percent of the votes cas...

Allergan Presented Positive Data from Clinical Studies of Investigational Abicipar

allergan
Allergan plc., a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners, a clinical-stage biopharmaceutical company developing a new class of d...

Allergan Expands REFRESH® Portfolio

Allergan plc, a leading global pharmaceutical company with a more than 70-year heritage in eye care, announced the launch of three new over-the-counter (OTC)  REFRESH® RELIEVA™ products: REFRESH® RELI...

FDA Approved Use of Allergan’s Juvéderm VOLUMA®

Allergan plc announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek au...

Allergan Reached Settlement with Plaintiffs in Federal Opioid Litigation

allergan
Allergan plc announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation. As part ...

Amgen and Allergan Announced Positive Results from Clinical Study of Rituxan®

research
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to...

Endo and Allergan Reach Settlement with Cuyahoga, Summit Counties Over Opioid Epidemic

In a scramble to avoid the first federal trial over the opioid epidemic, two drug companies have agreed to pay plaintiffs Cuyahoga and Summit counties a combined $15 million in lawsuit settlements.  ...

Allergan Launched Online Resource Related to Voluntary Global Recall of BIOCELL®

allergan
Allergan plc has launched an online resource for patients, surgeons and healthcare professionals related to the voluntary global recall of BIOCELL®  textured breast implants and tissue expanders annou...

Allergan Announced Voluntary Worldwide Recall of BIOCELL® Textured Breast Implants and Tissue Expand...

allergan
Allergan plc announced a voluntary worldwide recall of BIOCELL® textured breast implants and tissue expanders. Allergan is taking this action as a precaution following notification of recently updated...

Amgen and Allergan Introduce Two Biosimilars in the U.S.

molecule
Amgen and Allergan announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTI™ (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in th...

FDA Accepted Allergan’s NDA for Bimatoprost Sustained-Release

allergan
Allergan, a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Applic...

AbbVie to Acquire Allergan for $63bn

AbbVie Inc. and Allergan plc announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transactio...